$308
ICON is a diagnostics & research business based in the US. ICON shares (ICLR) are listed on the NASDAQ and all prices are listed in US Dollars. ICON employs 41,100 staff and has a trailing 12-month revenue of around $8.3 billion.
Our top picks for where to buy ICON stock
How to buy ICON stock
- Choose a stock trading platform. Use our comparison table
- Open an account. Provide your personal information and sign up.
- Fund your account. Deposit funds into your account by linking your banking information or transfer funds from another trading account.
- Search for the stock name – ICLR. Search for the stock by name or ticker symbol.
- Buy the stock. Place your order. It's that simple.
Buy ICON stock from these online trading platforms
Compare special offers, low fees and a wide range of investment options among top trading platforms.Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
ICON stock price (NASDAQ: ICLR)
Use our graph to track the performance of ICLR stocks over time.ICON shares at a glance
Latest market close | $308.00 |
---|---|
52-week range | $221.20 - $347.72 |
50-day moving average | $322.75 |
200-day moving average | $303.74 |
Wall St. target price | $368.87 |
PE ratio | 37.4488 |
Dividend yield | N/A (0%) |
Earnings per share (TTM) | $8.60 |
Is it a good time to buy ICON stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
ICON price performance over time
Historical closes compared with the close of $308 from 2024-09-05
1 week (2024-08-30) | -4.37% |
---|---|
1 month (2024-08-06) | -1.45% |
3 months (2024-06-06) | -4.35% |
6 months (2024-03-06) | -8.23% |
1 year (2023-09-06) | 19.99% |
---|---|
2 years (2022-09-06) | 47.54% |
3 years (2021-09-03) | 17.40% |
5 years (2019-09-06) | 98.01% |
Is ICON stock undervalued or overvalued?
Valuing ICON stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of ICON's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
ICON's P/E ratio
ICON's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 37x. In other words, ICON shares trade at around 37x recent earnings.
That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.
ICON's PEG ratio
ICON's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 1.2874. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into ICON's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
ICON's EBITDA
ICON's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $1.7 billion.
The EBITDA is a measure of a ICON's overall financial performance and is widely used to measure a its profitability.
ICON financials
Revenue TTM | $8.3 billion |
---|---|
Operating margin TTM | 13.32% |
Gross profit TTM | $2.2 billion |
Return on assets TTM | 4.13% |
Return on equity TTM | 7.77% |
Profit margin | 8.58% |
Book value | $115.74 |
Market Capitalization | $26.7 billion |
TTM: trailing 12 months
ICON share dividends
We're not expecting ICON to pay a dividend over the next 12 months.
Have ICON's shares ever split?
ICON's shares were split on a 2:1 basis on 12 August 2008. So if you had owned 1 share the day before before the split, the next day you'd have owned 2 shares. This wouldn't directly have changed the overall worth of your ICON shares – just the quantity. However, indirectly, the new 50% lower share price could have impacted the market appetite for ICON shares which in turn could have impacted ICON's share price.
ICON share price volatility
Over the last 12 months, ICON's shares have ranged in value from as little as $221.195 up to $347.7225. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while ICON's is 1.226. This would suggest that ICON's shares are a little bit more volatile than the average for this exchange and represent, relatively-speaking, a slightly higher risk (but potentially also market-beating returns).
ICON overview
ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, rest of Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies. It also offers clinical development services, including all phases of development, peri and post approval, data solutions, and site and patient access services; clinical trial management, consulting, and contract staffing services; and commercial services comprising clinical development strategy, planning and trial design, full study execution, and post-market commercialization. In addition, the company provides laboratory services, including bionanalytical, biomarker, vaccine, good manufacturing practice, and central laboratory services, as well as full-service and functional service partnerships to customers. Further, it offers adaptive trials, cardiac safety solutions, clinical and scientific operations, consulting and advisory, commercial positioning, decentralized and hybrid clinical trials, early clinical, laboratories, language services, medical imaging, real world intelligence, site and patient, and strategic solutions. The company serves pharmaceutical, biotechnology, and medical device industries, as well as government and public health organizations. ICON Public Limited Company was incorporated in 1990 and is headquartered in Dublin, Ireland.
Frequently asked questions
nullWhat percentage of ICON is owned by insiders or institutions?
Currently 0.653% of ICON shares are held by insiders and 99.851% by institutions. How many people work for ICON?
Latest data suggests 41,100 work at ICON. When does the fiscal year end for ICON?
ICON's fiscal year ends in December. Where is ICON based?
ICON's address is: South County Business Park, Dublin, Ireland, D18 X5R3 What is ICON's ISIN number?
ICON's international securities identification number is: USG4705A1000 What is ICON's CUSIP number?
ICON's Committee on Uniform Securities Identification Procedures number is: G4705A100
More guides on Finder
-
Options profit calculator
Use this calculator to quickly see potential outcomes of your options trades.
-
Best options trading platforms of 2024
SoFi, Robinhood, Tastytrade, Webull, Interactive Brokers, E*TRADE, eToro and others top our list for the best options trading platforms.
-
What is a covered call?
A covered call is an options trading strategy that allows you to generate income from stocks you already own.
-
GSD Capital review 2024
A look at GSD Capital’s highlights, limitations, fees and investment strategies.
-
Today’s best brokerage account bonuses [Signup and transfer promos]
Explore the best bonuses for opening a new brokerage account.
-
10 E*TRADE competitors worth your time
Looking for a discount broker like E*TRADE that offers something different? Here are some of the top alternatives to consider.
-
Charles Schwab vs. Fidelity
Charles Schwab and Fidelity are two powerhouse trading platforms for beginner and advanced investors.
-
Interactive Brokers review 2024: Tailored trading and investing
Interactive Brokers has advanced charting tools but a high net requirement to qualify.
-
Top 15 tech stocks to invest in for 2024
Discover the top tech stocks poised to lead innovation and offer substantial growth opportunities.
-
Wealthfront review: Low-cost automated and DIY investing
Learn about Wealthfront’s automated investing tools and services to see if it’s the right platform for you.
Ask a question